OutperformHealth

Venus Concept VERO $2.11 Time to Buy outperformhealth.com/venus-concept-…

@libertyx Whoa! 7 days wwith value moving up and down? That doesn’t make sense!

Did you know if you buy #bitcoin using a bank transfer at online exchanges (e.g. Coinbase / Gemini) or apps (Cash App) you won't be able to move/spend it for up to 1 week? For instant bitcoin, consider @libertyx. Bitcoin is sent as soon as you make your debit card or cash payment

This is so huge Tried out a @libertyx cashier near my house this weekend The smoothest cash/#btc transaction I've ever had This seals the deal, LibertyX is my favorite #bitcoin on ramp at the moment

LibertyX is the fiture of bitcoin!

#radiationsafety, #cathlab, #cardiology

#COVID19 South Korea daily new cases declines again to 76, lowest since 2/22 - Total cases: 8,086➡️8,162 - Deaths: 72➡️75 - Total tested: 261,335➡️268,212 Very impressive how huge amount of work on broad testing + tracing + isolating is paying off against the #coronavirus!

Moving fast towards commercialization of our biological testing platform already in use by @BioGeneratorSTL portfolio co. Wugen. #biotech #drugdiscovery #research #multiplex #inflammation #cardiovascular #biomarkers eqstl.com/adarza-biosyst…

Finally! Radiation protection for the staff without cumbersome changes. This company has it!

Profits Matter- Genomic Health (GHDX) and Exact Sciences (EXAS)… and now GenMark (GNMK) outperformhealth.com/profits-matter…

Quest for profitability and making an exit possible. $GNMK GenMark Diagnostics Announces CEO and Chairman Transition finance.yahoo.com/news/genmark-d… via @YahooFinance

6 Reasons Why Short Sellers Are Good for The Stock Market wp.me/p1U1by-3L outperformhealth.com/6-reasons-why-…

Accuray $ARAY upgraded to Buy BTIG analyst Marie Thibault set a $9.50 price target. The company's long-term revenue growth outlook of 8%-12%. She believes that Accuray remains significantly undervalued, trading at just 1X TTM revenues. Read more at: thefly.com/landingPageNew…

Accuray upgraded to Buy BTIG analyst Marie Thibault set a $9.50 price target. The company's long-term revenue growth outlook of 8%-12%. She believes that Accuray remains significantly undervalued, trading at just 1X TTM revenues. Read more at: thefly.com/landingPageNew…

@MedDeviceNews1 Oab?

Dan Lemaitre Named CEO of BlueWind Medical "BlueWind has the potential to revolutionize the treatment of OAB which impairs the quality of life of millions of patients in the US and around the world," said Lemaitre infomeddnews.com/dan-lemaitre-n…

The US equity market has changed for the better- We are entering a period of unprecedented investor friendliness outperformhealth.com/the-us-equity-…

Accelerate Diagnostics Looking Like T-Two $AXDX $TTOO outperformhealth.com/accelerate-dia…

Seeing this ad makes me think someone is worried about Disney Plus...

Hologic HOLX Price Oscillation not Appreciation $HOLX outperformhealth.com/hologic-holx-p…

@sternvascular @JBMatthews They look cute til your son is in a bunker in some god forsaken land and one of these is running at him with a grenade attached...

@JBMatthews Has nobody at MIT seen Terminator?? Might as well rename that lab Skynet

We’re doomed.

@QuisitiveInvest Quantifying research revenue is hard as payment is frequently based on trading volumes. Although that has been shifting. There also is another indirect revenue tie in banking revenues. A good research analyst can win banking assignments and open doors for the bankers.